Omliclo Surpasses 90% Market Share in Spain

Aptosma Selected as Supplier by Spanish Ministry of Health Procurement Agency

Celltrion to Expand Supply of Autoimmune Disease Treatments in Portugal in Second Half

Celltrion is accelerating its expansion in the European market by consecutively winning major pharmaceutical tenders in Spain and Portugal. After securing achievements in both regional and national tenders, the company plans to further strengthen its local direct sales and marketing strategies to scale up sales in the second half of the year.


Celltrion Accelerates European Expansion with Consecutive Tender Wins in Spain and Portugal View original image

On August 12, Celltrion announced that its chronic idiopathic urticaria and allergic asthma treatment, Omliclo (generic name: Omalizumab), successfully secured a leading position in the Spanish market.


According to Celltrion’s Spanish subsidiary, during the first half of the year, Omliclo was selected as the supplier in Omalizumab tenders conducted by four autonomous regional governments: Catalonia, Basque Country, Asturias, and Valencia. As prescriptions and supply through individual hospitals increased, Celltrion estimates the market share of Omliclo in Spain exceeded 90% as of June this year. The company explained that Omliclo's product competitiveness and locally tailored direct sales strategy were key contributors to its success.


Omliclo offers a 150mg autoinjector (AI) formulation not available in the original product, and features a longer shelf life and room-temperature stability data compared to the originator drug. Based on these advantages, Celltrion is intensifying its sales and marketing activities targeting local healthcare professionals and pharmacists, while also actively promoting the healthcare cost-saving benefits of switching to biosimilars.


Aptosma (Tocilizumab), an autoimmune disease treatment, is also expanding its prescription base in Spain. Aptosma was selected as a supplier in both the national tender led by INGESA, the Spanish Ministry of Health’s procurement agency, and separate regional government tenders. As a result, Aptosma achieved nearly 50% market share in Spain as of the second quarter of this year, cementing its position in the market. Celltrion’s distinctive strategy, such as exclusively launching a 400mg formulation in Spain not available with the originator product, has proven effective, according to industry analysis.


Chronic idiopathic urticaria and allergic asthma treatment 'Omaliclo' (active ingredient omalizumab). Celltrion

Chronic idiopathic urticaria and allergic asthma treatment 'Omaliclo' (active ingredient omalizumab). Celltrion

View original image

Celltrion continued to win major product tenders in Portugal as well. In national tenders held during the first half of the year, the entire portfolio of autoimmune disease treatments—including Remsima (Infliximab), Yuflyma (Adalimumab), and Stekyma (Ustekinumab)—was awarded supply contracts and began distribution in the first half, with supply expected to continue through the second half. In addition, both Omliclo and the ophthalmic disease treatment Eydenzelt (Aflibercept) have secured tenders, enabling Celltrion to expand its European portfolio from a focus on autoimmune diseases to include ophthalmology, according to market evaluations.



Sukkyoon Kang, head of Celltrion’s Spanish subsidiary, stated, "Our new products continue to win tenders in Spain and Portugal, so we expect sharply accelerating sales growth beginning in the second half as supply ramps up. We will strengthen marketing activities targeting key stakeholders and further solidify our market position by leveraging our differentiated product and direct sales competitiveness."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing